Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo (Q39674037)

13 September 2017

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo (English)

1 reference

13 September 2017

Diana Azzam

3

0 references

Bryan T. Hennessy

8

object named as

Bryan T Hennessy

1 reference

13 September 2017

Yi Chen

1

1 reference

13 September 2017

Edwin A Alvarez

2

1 reference

13 September 2017

Seth A Wander

4

1 reference

13 September 2017

Natalia Guggisberg

5

1 reference

13 September 2017

Mercè Jordà

6

1 reference

13 September 2017

Zhenlin Ju

7

1 reference

13 September 2017

Joyce M Slingerland

9

1 reference

13 September 2017

language of work or name

English

0 references

publication date

29 July 2010

1 reference

Breast Cancer Research and Treatment

13 September 2017

1 reference

13 September 2017

128

1 reference

13 September 2017

1

1 reference

13 September 2017

69-78

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1024-7

13 September 2017

0 references

cites work

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

The relationship between prognostic and predictive factors in the management of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Src family kinases and HER2 interactions in human breast cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Pharmacodynamic markers of perifosine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Non-parametric quantification of protein lysate arrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1024-7

10.1007/S10549-010-1024-7

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference